Published in final edited form as:

Expert Opin Drug Deliv. 2006 September ; 3(5): 647–662. doi:10.1517/17425247.3.5.647.

Growth factor delivery for oral and periodontal tissue engineering

Darnell Kaigler^{1,2}, Joni A Cirelli¹, and William V Giannobile, DDS, DMedSc^{†,3,4,5}

¹Research Fellow, Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA

²Research Fellow, Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr, Lobby M, Box 422, Ann Arbor, MI 48106, USA

³Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA

⁴Associate Professor, Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI, USA

⁵Najjar Endowed Professor of Dentistry and Director, Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr., Lobby M, Box 422, Ann Arbor, MI 48106, USA

Abstract

The treatment of oral and periodontal diseases and associated anomalies accounts for a significant proportion of the healthcare burden, with the manifestations of these conditions being functionally and psychologically debilitating. Growth factors are critical to the development, maturation, maintenance and repair of craniofacial tissues, as they establish an extracellular environment that is conducive to cell and tissue growth. Tissue-engineering principles aim to exploit these properties in the development of biomimetic materials that can provide an appropriate microenvironment for tissue development. These materials have been constructed into devices that can be used as vehicles for delivery of cells, growth factors and DNA. In this review, different mechanisms of drug delivery are addressed in the context of novel approaches to reconstruct and engineer oral- and tooth-supporting structures, namely the periodontium and alveolar bone.

Keywords

biomimetics; gene therapy; osteogenesis; periodontal regeneration; tissue repair; wound healing

1. Introduction

Oral diseases and oral manifestations of systemic diseases can create major functional deficits and impair patients' abilities to eat, drink and speak. The consequences of these conditions can also be profoundly debilitating aesthetically, with the resultant loss of facial symmetry and, in some instances, the ability to smile. The treatment of craniofacial hard and soft tissue anomalies accounts for a significant proportion of the total US healthcare burden, with dental caries (tooth decay) and periodontal disease (gum disease) representing two of the most prevalent diseases worldwide. In fact, tooth extraction secondary to periodontal disease, dental caries or trauma is universally one of the most commonly practiced surgical procedures [1]. Full-mouth tooth loss or complete edentulism was once a relatively common condition among middle-aged

[†] Author for correspondence Michigan Center for Oral Health Research, University of Michigan Clinical Center, 24 Frank Lloyd Wright Dr., Lobby M, Box 422, Ann Arbor, MI 48106, USA Tel: +1 734 998 1468; Fax: +1 734 998 7228; E-mail: wgiannob@umich.edu

adults, but is now most prevalent in older persons, affecting approximately one-third of adults who are ≥ 65 years of age [2-4]. For those adults in the US who have teeth, it is estimated that at least 35% who are ≥ 30 years of age possess periodontal disease, with 21.8% having a mild form and 12.6% having a moderate or severe form [5]. Additionally, by the age of 17, $> 80\%$ of the adolescent population is affected by dental caries [5,6].

The standard treatment for edentulism involves prosthetic replacements, such as full or partial dentures, or dental implants [7]. Although these prostheses can initially restore limited function and can produce satisfactory results, because these prostheses are artificial, over time, individuals often continue to be faced with aesthetic and functional challenges relative to the fit and stability of these devices [8]. Even though continuing efforts to prevent tooth loss exist, there is a need to re-examine the current methods of tooth replacement and to pursue evolving tissue-engineering strategies and technologies that will enable the development of biological materials to regenerate teeth and tooth-supporting structures (e.g., the periodontium).

In examining craniofacial disease beyond the oral cavity, oral and pharyngeal cancer is the sixth most common cancer in the developed world. Each year, an estimated 28,900 Americans are diagnosed with this form of cancer and > 7400 die each year as a result of it [6]. Radiation therapy is often employed as a treatment for these individuals, but frequently aggressive resective surgery is also adjunctively performed to remove remaining affected tissues. Even if radiation treatment and resective surgery are successful in eradicating all damaged and diseased cells and tissues, the affected area is often left functionally compromised. Although prosthetic replacements and plastic reparative procedures are often performed in the reconstructive phases of therapy, regenerative outcomes are often undesirable relative to the restoration of function and aesthetics.

Craniofacial deformities are among the most common of all birth defects, with cleft lip and cleft palate among the more common birth defects in the US, occurring in ~ 1 to 2 of 1000 births. Adding to the burden of treatment of the condition itself is the burden of the lifetime cost of treating children born with cleft lip or cleft palate, which is estimated to be US\$697 million [9]. Surgery, dental care, psychological counselling and rehabilitation may help ameliorate the physical and social problems, but these also pose a tremendous financial cost to individuals and caregivers. Innovative advances in molecular biology are providing great insight on the function of genes that are important in forming the craniofacial structures. This information may ultimately build the necessary foundation for developing better treatments.

The science of tissue engineering is a multidisciplinary field that aims to restore and regenerate tissues and organs that have been compromised, damaged or lost [10]. Clinical success is highly dependent on the development of new naturally derived materials and synthetic biomimetic scaffolds that offer renewed hope for the treatment of craniofacial hard and soft tissue defects and disorders that are secondary to disease or injury. This review addresses the fundamental process of wound healing and the important growth factors involved, the development of biomaterials that are capable of delivering these growth factors to regenerative sites, and novel tissue-engineering approaches for oral and periodontal tissue engineering and regenerative medicine.

2. Growth factors for wound repair

Understanding the complex processes of wound healing has been a challenge for researchers for many years. Recently, advances in the areas of cellular and molecular biology have allowed the elucidation of functions of growth factors and their participation in the different phases of wound healing. Restoration of normal form and function is the ultimate goal of regenerative approaches for tissues disrupted by trauma, surgical resection or infectious disease. However,

if the functional integrity of the tissue is not achieved, the process of repair will take place and a fibrous tissue will replace the original tissue [11]. Recent *in vitro* and *in vivo* studies have confirmed that growth factors can improve the capacity of tissues to regenerate, improving cellular chemoattraction, differentiation and proliferation. Growth factors are natural biological mediators that regulate important cellular events involved in tissue repair by binding to specific cell surface receptors [12]. After reaching specific target cells, growth factors induce intracellular signalling pathways, which result in the activation of genes that change cellular activity and phenotype [13]. However, the effect of each growth factor is regulated through a complex system of feedback loops that involve other growth factors, enzymes and binding proteins [14,15]. The study of many different growth factors and other cytokines, each one with several functions during the different phases of wound healing, have been performed in order to define their proper application for therapeutic purposes [14,15] (Table 1).

Healing of osseous tissue is regulated by growth factors and other cytokines in a sequence of overlapping events similar to cutaneous wound repair. In ideal circumstances, this process mimics embryonic bone development, allowing the replacement of damaged bone with new bone, rather than with fibrous scar tissue. This process is driven by cellular and molecular mechanisms controlled by the TGF- β superfamily of genes, which encodes a large number of extracellular signalling growth factors [16]. Bone morphogenetic proteins (BMPs) are a well-studied group of these growth factors involved in the processes of bone healing; and the human genome encodes at least 20 of these multifunctional polypeptides [17]. Among several of its functions, BMPs induce the formation of both bone and cartilage by stimulating the cellular events of mesenchymal progenitor cells. However, only a subset of BMPs, most notably BMP-2, -4, -7 and -9, have osteoinductive activity, a property of inducing *de novo* bone formation by themselves [18]. Studies involving mutations of BMP ligands, receptors and signalling proteins have shown important roles of BMPs in embryonic and postnatal development. Severe skeletal deformation, development of osteoporosis, reduction in bone mineral density and bone volume are all aberrations associated with disrupted and dysregulated BMP signalling [19,20]. Further extraskeletal effects of BMPs have been examined, with mice deficient for BMP-2, -4 or -7 having severe organ deficiencies and dying shortly after birth [21-23].

Several other growth factors produced by osteogenic cells, platelets and inflammatory cells participate in bone healing, including IGF-1 and -2, TGF- β_1 , PDGF and FGF-2 [24]. The bone matrix serves as a reservoir for these growth factors and BMPs, and are activated during matrix resorption by matrix metalloproteases [25,26]. Additionally, the acidic environment that develops during the inflammatory process leads to activation of latent growth factors [27], which assist in the chemo-attraction, migration, proliferation and differentiation of mesenchymal cells into osteoblasts or chondroblasts [27]. All of these functions are driven by a complex mechanism of interaction among growth factors and other cytokines, which are influenced by several regulatory factors [28].

3. Approaches for growth factor delivery

A key variable for successful tissue regeneration and engineering is the environment in which cells and tissues grow. The concepts of guided tissue regeneration (GTR) and guided bone regeneration aim to optimise this variable, in that different membranes are used in these procedures as barriers. These barriers support the ingrowth of more favourable tissue regenerative cells (i.e., periodontal ligament [PDL] cells, bone cells), whilst selectively excluding non-desirable cells (i.e., gingival epithelial cells, connective tissue cells) from reconstruction sites [29]. These membranes also support the establishment of other critical parameters that are paramount to successful periodontal and bone regeneration, including: tenting and isolation (adaptation of the membrane to ensure adequate space will be maintained

for tissue regeneration); scaffolding (the membrane serves as a matrix-enabling organisation of tissue progenitor cells and newly forming vasculature); and stabilisation (the membrane protects the area from being mobilised during initial phases of healing and regeneration) [30-34]. Both resorbable and non-resorbable membranes have been used for these applications with comparable success, although a key advantage in the use of resorbable materials is that the need for re-entry into the regenerated site is eliminated [35,36]. Membranes derived from natural compounds (i.e., collagen) are degraded by an enzymatic process (biodegradation), catalysed by cells in the local microenvironment and within the developing tissue [37,38], but synthetic polymers (i.e., derivatives of polylactic and polyglycolic acid) are hydrolysed (bioabsorption) into the natural metabolites lactic acid and glycolic acid [39,40]. The polylactic scaffolds are popularly employed due to familiarity with their favourable biocompatible properties, which helps minimise an undesirable inflammatory response. In addition, the development of both naturally derived and synthetic materials allows the degradation properties to be controlled by the composition and ratios of compounds that comprise the material. A key advantage of this, particularly with more recently developed polymers, is that these properties can be tailored to meet the specific needs of the application with regard to how long one desires to have the material maintained [34,41-43].

The development and maintenance of an appropriate environment for tissue regeneration and engineering is critical not only for GTR and guided bone regeneration approaches, but also in the use of gene, protein and cell therapy approaches. Thus, these tissue-engineering strategies involve the use of different polymer systems to serve as synthetic extracellular matrices. In these strategies, polymers serve as delivery depots not only for growth factors and DNA molecules, but also for cells. Specifically, cells can be delivered after *ex vivo* expansion to be combined with biomaterials to deliver cells, but also as a scaffold template to allow cells to continually proliferate and differentiate into new tissues (Figure 1). Successful regeneration and engineering of a wide variety of oral structures have been demonstrated with this cell transplantation approach, and these tissues include bone [44,45], PDL [46], oral mucosa [47], skin [48] and teeth [49]. Cells can also be genetically modified *ex vivo* prior to implantation, creating a combined gene therapy–cell transplantation approach [50].

Two common types of polymeric materials used in growth factor delivery strategies are natural collagen-derived materials [37,38,51] and synthetic polymers of lactic and glycolic acid (i.e., poly[lactide-co-glycolide]) [40,52]. Extracellular matrix-derived macromolecules such as collagen have been used for many years in biomaterial application [53], and it is now possible to create artificial analogues of extracellular matrix proteins using recombinant DNA technology [54]. Collagen is degraded by cells within regenerating tissue as it develops, and biodegradable synthetic polymers such as poly(lactide-co-glycolide) are hydrolysed into natural metabolites, lactic acid and glycolic acid by the action of water at regenerated sites. The poly(lactide-co-glycolide) scaffolds are popularly employed due to familiarity with their functional properties and uses in other applications (e.g., biodegradable sutures). Additionally, growth factors and DNA can be incorporated into these materials and released in a controlled, sustained manner to enhance tissue regeneration [44,55].

A variety of new injectable materials such as hydrogels are also being developed for growth factor delivery applications and have been of special interest [56,57]. These injectables are especially attractive because, in clinical application, they can allow for minimally invasive delivery of inductive molecules. A great deal of insight has been gained in evaluating the *in vivo* performance of engineered biomaterials consisting of polysaccharides. As an example, alginate hydrogels bearing cell-adhesion ligands have been used as scaffolds for cell encapsulation and transplantation, and have yielded promising results in experiments directed toward the engineering of bone tissue [58]. An alternative to synthesising polymers composed of these natural components is the synthesis of biomimetic polymers. These polymers combine

the information content and multifunctional character of natural materials with the tailorability (ability to impart appropriate mechanical properties) of synthetic polymers. This hybrid concept has been used in the binding of polymers with specific amino acids (such as the tripeptide sequence RGD) that are capable of regulating cell adhesion [59,60].

Another area of increasing attention has been the development of shape-memory materials that have one shape at one temperature and another shape at a different temperature [61,62]. These materials have the ability to memorise a permanent shape that can be substantially different from an initial temporary shape. As an example, a bulky device could potentially be introduced into a surgical site as a temporary shape (such as a string or freely flowing material), penetrate through a small area of the site, and then be expanded in response to different cues into a permanent shape (i.e., a stent or a sheet). The response signals that stimulate the changes in shape in response to environmental cues are incorporated within the material during its fabrication. These materials have been designated as 'smart' materials, having the ability to appropriately change their structural and functional material properties in response to environmental cues [63]. These materials have also demonstrated great promise and the ability to control their built-in signalling is what makes them attractive for growth factor delivery strategies.

4. Growth factor applications for oral and periodontal tissue engineering

Therapeutic application of growth factors to restore damaged tissues aims at regeneration through biomimetic processes, or mimicking the processes that occur during embryonic and post-natal development [15]. The complexity of these events suggests that creating an optimal regenerative environment requires the combination of different growth factors as found in natural reparative processes. The use of a single recombinant growth factor may also induce several molecular, biochemical and morphological cascades that will result in tissue regeneration [14].

A number of studies (Table 2) have evaluated the application of recombinant growth factors alone or associated with other growth factors or biomaterials for regeneration of different oral tissues, including maxillary/mandibular bone [15], salivary glands [64], dentin–pulp complexes [65,66] and periodontal structures [67]. In the periodontium, regenerative treatment has been a challenge due to morphological and functional specificities of each component of tooth-supporting tissues. The most studied growth factors for periodontal regeneration have been PDGF, IGF, FGF-2, TGF- β and different BMPs.

PDGF was the first growth factor to be evaluated in preclinical periodontal and peri-implant regenerative studies. Proliferation, migration and matrix synthesis were observed on cultures of periodontal cells stimulated by PDGF, including gingival and PDL fibroblasts, cementoblasts, preosteo-blasts and osteoblastic cells [68-73]. These effects were shown to be time- and dose dependent [73]. The PDGF family is composed of four growth factors: PDGF-A, -B, and the most recently discovered PDGF-C and -D [74]. All of these participate in the wound-healing process, but, until now, only the three isoforms PDGF-AA, BB and AB were evaluated in periodontal therapy. PDGF-BB is the most effective on PDL cell mitogenesis and matrix biosynthesis [75,76]. Several preclinical studies were performed using the combination of PDGF-BB and IGF-I for periodontal and peri-implant bone regeneration [77-82], culminating in the first study in humans using growth factors for periodontal regeneration [83]. In a human Phase I/II clinical trial, PDGF/IGF-I were considered safe when applied topically to periodontal osseous lesions, resulting in a significant improvement in bone growth and fill of periodontal defects, compared with standard therapy [83]. The evaluation of PDGF alone was demonstrated in two preclinical studies in dogs. Alveolar bone defects of critical size were completely regenerated after treatment with PDGF-BB associated to GTR [84,85].

The results were superior to the same treatment without PDGF. The authors concluded that PDGF stimulated formation of fibrous connective tissue in an early stage of repair, filling and stabilising the wound. In a subsequent regenerative stage, the fibrous tissue was substituted with new bone and PDL [84]. This conclusion is supported by another study that shows enhanced fibroblast proliferation in an early periodontal wound healing, after treatment of alveolar bone defects in dogs with PDGF [86]. PDGF-BB alone was evaluated in humans in three recent studies [87-89]. The first two studies [87,88] evaluated PDGF-BB associated with demineralised freeze-dried bone allograft in the treatment of different types of critical size periodontal bone defects. Histological evidence of periodontal regeneration was provided by these proof-of-principle studies. The most recent study [89], a large multi-centre Phase III clinical trial, evaluated the benefits of recombinant human PDGF-BB (rhPDGF-BB) associated with synthetic β -tricalcium phosphate in the treatment of periodontal bone defects in 180 patients. The study demonstrated that the use of rhPDGF-BB is safe and improves bone fill and attachment of gingival tissue to root surfaces of involved teeth.

The angiogenic and fibroblast stimulatory properties of FGF-2 during wound healing and its chemotactic and proliferative effects on PDL cells [90,91] suggest its use for periodontal regenerative therapeutic approaches. In preclinical studies, this growth factor was evaluated for the treatment of different types of periodontal bone defects, in dogs [92-95] and non-human primates [96]. Despite different concentrations of FGF-2 and different delivery systems used in the studies, all showed an improvement in the periodontal tissue regeneration, compared with control groups. Studies that evaluated more than one concentration of FGF-2 suggested that its effects are dose dependent [92,96].

The involvement of TGF- β in several important functions during wound healing makes it an important growth factor in this process and suggests its use for therapeutic approaches. However, TGF- β can control gene expression either positively or negatively, a factor that can interfere with its therapeutic use [97]. TGF- β_1 , the most abundant isoform of the TGF- β family and found primarily in the platelets and osseous tissue, has been used for this application. The results of rhTGF- β_1 for periodontal regeneration have not been consistent preclinically as shown in canine and ovine investigations [98-100]. Two studies in supra-alveolar critical bony defects in dogs showed little advantages in new bone formation and no improvement in cementum regeneration when treated with rhTGF- β_1 with or without GTR [98,99]. In another application, TGF- β_1 was demonstrated to increase the amount of bone healing adjacent to dental implants in minipigs [97]. The limited number of studies and inconsistent results suggest that more study is needed to confirm the beneficial effects of rhTGF- β_1 on periodontal regeneration.

An important group of proteins for therapeutic applications, of the well-studied TGF- β superfamily, is the BMPs. BMPs -2, -4, -7 and -12 have all been evaluated for periodontal and peri-implant bone regeneration [67]. From this group of proteins, BMP-2 has been the most studied for bone and periodontal regenerative treatment [101-106].

Several preclinical studies demonstrate significant improvement of alveolar bone regeneration in different types of periodontal defects after treatment with rhBMP-2 via different carriers. Cementum regeneration was also stimulated by rhBMP-2, although not significantly in some reports [104,107,108]. Ankylosis was also occasionally reported to affect periodontal regeneration associated with rhBMP-2 treatment [102,103,109]. Ankylosis (fusion of the tooth and the alveolar bone) is more frequent in the cervical area of the exposed root and seems to be associated with rapid osteogenesis, especially in submerged tooth models. However, a recent study demonstrated a tendency of resolution of the ankylosis over time when evaluated 12 weeks after treatment [110].

Another important therapeutic application of BMPs is for maxillary bone regeneration to allow replacement of lost teeth by osseointegrated dental implants. This approach involves the regeneration of peri-implant bone after implant fixation or bone height improvement in areas below the maxillary sinus. Preclinical [111-116] and clinical [117-120] studies have shown improved bone formation after treatment with BMP-2. However, the use of different carriers and the association of barrier membrane (GTR technique) or other biomaterials seem to be critical factors in influencing the therapeutic outcome.

BMP-7 or osteogenic protein-1 is a potent modulator of osteogenesis and bone cell differentiation [121]. Its effect in periodontal-regenerative treatment was evaluated in bony defects around tooth roots in preclinical studies [121-123]. Significant improvement on bone and cementum regeneration was observed in dogs [121]. An extensive cementogenesis was considered the most significant effect of BMP-7 in bony defects in baboons [122,123]. Improvement of bone formation around titanium implants was also demonstrated by studies in animals [124,125], although no significant benefit was observed when rhBMP-7 was compared with bone grafts for maxillary bony defects in preclinical [126] and pilot human clinical studies [127].

The potential of BMP-12 to repair tendon and PDL tissues has been shown *in vitro* and *in vivo* studies [128]. A recent preliminary study in dogs compared rhBMP-12 with rhBMP-2 for the treatment of periodontal defects [129]. The results showed less bone and more functionally oriented PDL between the new bone and new cementum after BMP-12 treatment, contrasting with a more parallel fibre arrangement than BMP-2-treated defects.

The results from preclinical and initial clinical studies using growth factors are encouraging; however, some limitations exist with respect to bone volume and predictability. Although *in vitro* studies have elucidated the role of growth factors in the cellular events of the different type of cells, several factors may influence the results *in vivo*. Limitations that restrict optimal responses indicate growth factor delivery included the short half-life of growth factors after being delivered *in vivo*. This may be due to proteolytic degradation, rapid diffusion and the solubility of delivery vehicles in chronic periodontal wounds [12].

Enamel matrix derivative (EMD), an alternative approach for periodontal regeneration, uses proteins that are derived from embryonic enamel matrix with the purpose of mimicking the specific events that occur during the development of the periodontal tissues [130]. EMD uses propylene glycol alginate as a vehicle in a viscous formulation. After coating the tooth root close to the periodontal defect, the propylene glycol alginate viscosity is reduced under physiological conditions and facilitates EMD release and precipitation [131]. Recent systematic reviews were published on the efficacy of this product in the treatment of periodontal bony defects supporting its use [132-134].

5. Next generation approaches for periodontal tissue engineering

The development of new delivery devices has improved the efficacy of growth factor delivery *in vivo*. Bioabsorbable controlled-release scaffolds have been fabricated to sequester growth factors and release them at optimal doses in a timely manner depending on the biological demand of the target tissue [135]. Several studies have shown release of growth factors for up to 15 days when associated with poly(lactate-coglycolide) scaffold-containing microspheres [136,137].

However, even with optimal scaffolds, the local application of growth factors often requires a large amount of protein to stimulate significant effects *in vivo*, which increases the risk of unwanted side effects [138]. An alternative approach using gene transfer may have the advantage of transferring into specific cells with specific promoters, using appropriate vectors,

to attain a sustained gene expression and more efficient way of delivering *in vivo* [67]. A method of treating salivary gland functional deficiencies makes use of this gene therapy approach. The aim of this method is to drive existing non-secretory ductal epithelial cells into secretory cells capable of fluid movement, and success in animal models has been demonstrated [139,140].

6. Gene delivery for alveolar bone engineering

The improvement in the knowledge of the genetic and cellular mechanisms of human diseases allowed the development of a new therapeutic approach for congenital and acquired diseases via gene therapy. This new clinical strategy can be defined as an introduction of specific genetic changes by homologous vector sequences [141]. Although initially designed to permanently correct a single gene in monogenetic disorders, gene therapy methods have included modification or elimination of malignant cells, modulation of host defences and re-engineering of diseased organs or tissues. With this approach is the potential to genetically modify the cells to express the required growth factors for bone regeneration and, more specifically, periodontal regeneration [142] (Figure 2).

A vector is a carrier that helps to circumvent the natural barriers to DNA internalisation to the cell nucleus, where it can use the cellular machinery to express the exogenous gene [143]. In general, gene delivery can be approached by using viral or non-viral vectors. Viral vectors consist of viruses that are transformed into gene-delivery vehicles by replacing part of their genome with a therapeutic gene. Usually, the gene of interest is subcloned in a plasmid under the control of the cytomegalo-virus promoter before recombination with the viral backbone DNA. The substitution of the original gene promoter has the purpose of enhancing transcription efficiency [144]. The most commonly employed vectors are retrovirus, lentivirus, adenovirus or adeno-associated virus.

Each of these viral vectors has characteristics that make it more or less appropriate for specific applications. Retrovirus, lentivirus and adeno-associated virus have their genomes integrated into host chromosomes and are more indicated for applications requiring persistent and stable genetic changes [145]. Adenovirus (Ad) instead persists in a non-integrated form and produces a more transient transgene expression, which is not an issue for some applications, such as bone regeneration. Ad is also characterised by a high transduction efficiency and, although it has been the most-used vector, has the disadvantage of eliciting an immunological response. In general, safety is the primary concern and safety issues include not only immunogenical reactions, but also the risk of conversion of a non-replicative vector to a wild-type virion and tumorigenesis [146].

Non-viral vectors include plasmid DNA and synthetic vectors that consist of complexes of plasmid DNA with cationic lipids and polymers, known as lipoplexes and polyplexes, respectively. Although they present improved safety and are more easily manufactured than viral vectors, they have low gene-transfer efficiency and, in some cases, toxicity and *in vivo* instability [147].

The application of gene therapy for tissue engineering has proved to be effective and has extended to multiple areas of medicine. Ad has been largely employed for this purpose as it is non-integrating and is a relatively safe virus, whilst inducing high levels of transient gene expression and transduction of multiple cell types. In the oral complex, gene therapy has been evaluated in the regenerative treatment of bony anomalies, salivary gland injuries, dental pulp repair and periodontal diseases [142]. Table 3 displays recent applications of gene therapy in oral and craniofacial disorders.

In periodontology, the role of PDGF in periodontal regeneration has been discussed in the context of bone [148] and other tissues [58], highlighting the potential of PDGF gene delivery

for periodontal engineering. The initial studies evaluated the ability of Ad-PDGF-A to affect cells derived from the periodontia [149]. Osteoblasts, PDL fibroblasts, gingival fibroblasts and cementoblasts displayed effective expression of the *PDGF-A* gene for up to 7 days following gene delivery, which resulted in enhanced mitogenic and proliferative responses in these cells [149]. Dermal fibroblasts also presented prolonged signalling events and downregulation of PDGF α R up to 96 h after Ad-PDGF-A delivery [150].

Simulating a clinical condition, a three-dimensional *ex vivo* wound-healing model used human gingival fibroblast cultures to evaluate the effects of gene transfer of Ad-PDGF-A and Ad-PDGF-B on cell repopulation and wound fill [50]. The expression of PDGF genes was prolonged for up to 10 days. Ad-PDGF-B resulted in a twofold increased rate of defect fill and fourfold greater cell densities inside the defect than Ad-PDGF-A or control groups. The upregulation of genes associated with PDGF signalling (PI₃ kinase) and fibroblast migration (integrin α_5) suggested modulation of cellular and molecular events by Ad-PDGF-B therapy [50].

An early evaluation of gene therapy for periodontal regeneration *in vivo* used *ex vivo* gene transfer in alveolar bone wounds in rats [151]. Syngeneic dermal fibroblasts were transduced *ex vivo* with Ad-BMP-7, seeded onto gelatin carriers, then transplanted to mandibular alveolar bone defects in a wound-repair model. The treatment stimulated periodontal wound healing, including bone, PDL and cementum. However, the *ex vivo* gene transfer has the limitations of cell procurement issues and the need for an additional surgical procedure for biopsy harvest. To overcome these disadvantages, an *in vivo* viral gene delivery approach was evaluated [152]. A collagen matrix containing Ad-PDGF-B was applied in a similar osseous defect model. Localised transgene expression was observed for up to 3 weeks, resulting in proliferative and regenerative effects on periodontal cells. A fourfold increase in bridging bone and a sixfold increase in cementum repair was observed in the Ad-PDGF-B-treated sites in comparison to controls [152].

Another approach using *in vivo* gene delivery evaluated bone regeneration after the treatment of large defects surrounding dental implants using Ad-BMP-7 that were associated with a collagen matrix [153]. The treatment resulted in enhancement of alveolar bone defect fill, coronal new bone formation and new bone-to-implant contact.

The initial preclinical studies with gene delivery point to the feasibility of using gene therapy for periodontal tissue engineering. Future studies need to be conducted to better evaluate the advantages and disadvantages of different vectors and elucidate safety concerns.

7. Expert opinion

Major advances have been made over the past decade in the reconstruction of complex periodontal and alveolar bone wounds that have resulted from disease or injury. For future growth and development of the field over the next 5 – 10 years, several key areas will need to be addressed to promote greater predictability of oral tissue-engineering procedures. These include the following: i) improved delivery methods (including use of natural, polymeric and ceramic biomaterials); ii) consideration of dual and multi-factor release; iii) anatomical defect reconstruction three-dimensionally; and iv) combined efforts to deliver anti-infective molecules with regenerative growth factors. Developments in scaffolding matrices for cell, protein and gene delivery have demonstrated significant potential to provide ‘smart’ biomaterials that can interact with the matrix, cells and bioactive factors. The targeting of signalling molecules or growth factors (via proteins or genes) to craniofacial structures and periodontia has led to significant new knowledge generation using factors that promote cell replication, differentiation, matrix biosynthesis and angiogenesis. A major challenge that needs to be addressed in order to take oral tissue engineering to the next level is the modulation of

the exuberant host response to microbial contamination of the periodontal and oral wound micro-environment. For improvements in the outcome of oral and periodontal regenerative medicine, scientists will need to examine dual delivery of host modifiers or anti-infective agents to optimise the results of therapy. Further advancements in the field will continue to rely heavily on multidisciplinary approaches combining engineering, dentistry, medicine and infectious disease specialists in repairing the complex periodontal wound environment.

Acknowledgments

This work has been supported by NIH/NIDCR grants R01-DE 015384, R01-DE-13397, DE 016619 and the AO Foundation Switzerland to WV Giannobile.

Bibliography

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. COCHRAN D. Implant therapy I. Ann. Periodontol 1996;1(1):707–791. [PubMed: 9118278]
2. MARCUS PA, JOSHI A, JONES JA, MORGANO SM. Complete edentulism and denture use for elders in New England. J. Prosthet. Dent 1996;76(3):260–266. [PubMed: 8887798]
3. DOUGLASS CW, SHIH A, OSTRY L. Will there be a need for complete dentures in the United States in 2020? J. Prosthet. Dent 2002;87(1):5–8. [PubMed: 11807476]
4. NATIONAL CENTER FOR HEALTH STATISTICS. National Health Interview Survey. 1998
5. ALBANDAR JM, BRUNELLE JA, KINGMAN A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J. Periodontol 1999;70(1):13–29. [PubMed: 10052767]
6. BELTRÁN-AGUILAR E, BARKER L, CANTO M, et al. Surveillance for dental caries, dental sealants, tooth retention, edentulism, and enamel fluorosis – United States, 1988-1994 and 1999-2002. MMWR 2005;54(3):1–44.
7. TANG CS, NAYLOR AE. Single-unit implants versus conventional treatments for compromised teeth: a brief review of the evidence. J. Dent. Educ 2005;69(4):414–418. [PubMed: 15800254]
8. MISCH, CE. Dental Implant Prosthetics. Elsevier Mosby; St. Louis, MO, USA: 2005.
9. CENTER FOR DISEASE CONTROL AND PREVENTION. Economic costs of birth defects and cerebral palsy – United States, 1992. MMWR 1995;44(37):694–699. [PubMed: 7666849]
10. LANGER R, VACANTI JP. Tissue engineering. Science 1993;260(5110):920–926. [PubMed: 8493529]
11. LE AD, BASI DL, ABUBAKER AO. Wound healing: findings of the 2005 AAOMS Research Summit. J. Oral Maxillofac. Surg 2005;63(10):1426–1435. [PubMed: 16182909]
12. GIANNOBILE WV. Periodontal tissue engineering by growth factors. Bone 1996;19(1 Suppl):23S–37S. [PubMed: 8830996]
13. ANUSAKSATHIEN O, GIANNOBILE WV. Growth factor delivery to re-engineer periodontal tissues. Curr. Pharm. Biotechnol 2002;3(2):129–139. [PubMed: 12022256]
14. RIPAMONTI U, HERBST NN, RAMOSHEBI LN. Bone morphogenetic proteins in craniofacial and periodontal tissue engineering: experimental studies in the non-human primate *Papio ursinus*. Cytokine Growth Factor Rev 2005;16(3):357–368. [PubMed: 15951219]
15. SCHILEPHAKE H. Bone growth factors in maxillofacial skeletal reconstruction. Int. J. Oral Maxillofac. Surg 2002;31(5):469–484. [PubMed: 12418561]
16. BLAIR HC, ZAIDI M, SCHLESINGER PH. Mechanisms balancing skeletal matrix synthesis and degradation. Biochem. J 2002;364(Pt 2):329–341. [PubMed: 12023876]
17. BLUMENTHAL NM, KOH-KUNST G, ALVES ME, et al. Effect of surgical implantation of recombinant human bone morphogenetic protein-2 in a bioabsorbable collagen sponge or calcium phosphate putty carrier in intrabony periodontal defects in the baboon. J. Periodontol 2002;73(12):1494–1506. [PubMed: 12546100]

18. CHENG H, JIANG W, PHILLIPS FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). *J. Bone Joint Surg. Am* 2003;85-A(8):1544–1552. [PubMed: 12925636]
19. WU XB, LI Y, SCHNEIDER A, et al. Impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis in noggin-overexpressing mice. *J. Clin. Invest* 2003;112(6):924–934. [PubMed: 12975477]
20. MIKIC B, VAN DER MEULEN MC, KINGSLEY DM, CARTER DR. Long bone geometry and strength in adult BMP-5 deficient mice. *Bone* 1995;16(4):445–454. [PubMed: 7605705]
21. DUDLEY AT, LYONS KM, ROBERTSON EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. *Genes Dev* 1995;9(22):2795–2807. [PubMed: 7590254]
22. WINNIER G, BLESSING M, LABOSKY PA, HOGAN BL. Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev* 1995;9(17):2105–2116. [PubMed: 7657163]
23. ZHANG H, BRADLEY A. Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* 1996;122(10):2977–2986. [PubMed: 8898212]
24. SYKARAS N, OPPERMAN LA. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? *J. Oral Sci* 2003;45(2):57–73. [PubMed: 12930129]
25. BAYLINK DJ, FINKELMAN RD, MOHAN S. Growth factors to stimulate bone formation. *J. Bone Miner. Res* 1993;8(Suppl 2):S565–S572. [PubMed: 8122528]
26. JANSSENS K, TEN DIJKE P, JANSSENS S, VAN HUL W. Transforming growth factor-beta1 to the bone. *Endocr. Rev* 2005;26(6):743–774. [PubMed: 15901668]
27. LINKHART TA, MOHAN S, BAYLINK DJ. Growth factors for bone growth and repair: IGF, TGF- β and BMP. *Bone* 1996;19(Suppl 1):1S–12S. [PubMed: 8830994]
28. KING GN, COCHRAN DL. Factors that modulate the effects of bone morphogenetic protein-induced periodontal regeneration: a critical review. *J. Periodontol* 2002;73(8):925–936. [PubMed: 12211503]
29. NYMAN S, GOTTLOW J, KARRING T, LINDHE J. The regenerative potential of the periodontal ligament. An experimental study in the monkey. *J. Clin. Periodontol* 1982;9(3):257–265. [PubMed: 6954167]
30. GOTTLOW J, NYMAN S, KARRING T. Maintenance of new attachment gained through guided tissue regeneration. *J. Clin. Periodontol* 1992;19(5):315–317. [PubMed: 1517475]
31. NYMAN S, LINDHE J, KARRING T, RYLANDER H. New attachment following surgical treatment of human periodontal disease. *J. Clin. Periodontol* 1982;9(4):290–296. [PubMed: 6964676]
32. SCHENK RK, BUSER D, HARDWICK WR, DAHLIN C. Healing pattern of bone regeneration in membrane-protected defects: a histologic study in the canine mandible. *Int. J. Oral Maxillofac. Implants* 1994;9(1):13–29. [PubMed: 8150509]
33. LANG NP, WETZEL AC, STICH H, CAFFESSE RG. Histologic probe penetration in healthy and inflamed peri-implant tissues. *Clin. Oral Implants Res* 1994;5(4):191–201. [PubMed: 7640332]
34. OH TJ, MERAW SJ, LEE EJ, GIANNIBILE WV, WANG HL. Comparative analysis of collagen membranes for the treatment of implant dehiscence defects. *Clin. Oral Implants Res* 2003;14(1):80–90. [PubMed: 12562369]
35. GOTTLOW J. Guided tissue regeneration using bioresorbable and non-resorbable devices: initial healing and long-term results. *J. Periodontol* 1993;64(Suppl 11):1157–1165. [PubMed: 8295105]
36. ZITZMANN NU, NAEF R, SCHARER P. Resorbable versus nonresorbable membranes in combination with Bio-Oss for guided bone regeneration. *Int. J. Oral Maxillofac. Implants* 1997;12(6):844–852. [PubMed: 9425767]
37. CIRELLI JA, MARCANTONIO E Jr, ADRIANA R, et al. Evaluation of anionic collagen membranes in the treatment of class II furcation lesions: an histometric analysis in dogs. *Biomaterials* 1997;18(18):1227–1234. [PubMed: 9300557]
38. PITARU S, TAL H, SOLDINGER M, NOFF M. Collagen membranes prevent apical migration of epithelium and support new connective tissue attachment during periodontal wound healing in dogs. *J. Periodontal Res* 1989;24(4):247–253. [PubMed: 2528624]
39. KIM BS, MOONEY DJ. Development of biocompatible synthetic extracellular matrices for tissue engineering. *Trends Biotechnol* 1998;16(5):224–230. [PubMed: 9621462]

40. HARRIS LD, KIM BS, MOONEY DJ. Open pore biodegradable matrices formed with gas foaming. *J. Biomed. Mater. Res* 1998;42(3):396–402. [PubMed: 9788501]
41. BUNYARATAVEJ P, WANG HL. Collagen membranes: a review. *J. Periodontol* 2001;72(2):215–229. [PubMed: 11288796]
42. ALSBERG E, KONG HJ, HIRANO Y, et al. Regulating bone formation via controlled scaffold degradation. *J. Dent. Res* 2003;82(11):903–908. [PubMed: 14578503]
43. KONG HJ, KAIGLER D, KIM K, MOONEY DJ. Controlling rigidity and degradation of alginate hydrogels via molecular weight distribution. *Biomacromolecules* 2004;5(5):1720–1727. [PubMed: 15360280]
44. HUANG YC, KAIGLER D, RICE KG, KREBSBACH PH, MOONEY DJ. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. *J. Bone Miner. Res* 2005;20(5):848–857. [PubMed: 15824858]
45. KAIGLER D, KREBSBACH PH, WEST ER, et al. Endothelial cell modulation of bone marrow stromal cell osteogenic potential. *FASEB J* 2005;19(6):665–667. [PubMed: 15677693]
46. ZHAO M, JIN Q, BERRY JE, et al. Cementoblast delivery for periodontal tissue engineering. *J. Periodontol* 2004;75(1):154–161. [PubMed: 15025227]
47. IZUMI K, SONG J, FEINBERG SE. Development of a tissue-engineered human oral mucosa: from the bench to the bed side. *Cells Tissues Organs* 2004;176(13):134–152. [PubMed: 14745242]
48. PARENTEAU N. Skin: the first tissue-engineered products. *Sci. Am* 1999;280(4):83–84. [PubMed: 10232963]
49. YOUNG CS, ABUKAWA H, ASRICAN R, et al. Tissue-engineered hybrid tooth and bone. *Tissue Eng* 2005;11(910):1599–1610. [PubMed: 16259613]
50. ANUSAKSATHIEN O, WEBB SA, JIN QM, GIANNOBILE WV. Platelet-derived growth factor gene delivery stimulates ex vivo gingival repair. *Tissue Eng* 2003;9(4):745–756. [PubMed: 13678451]
51. POSTLETHWAITE AE, SEYER JM, KANG AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. *Proc. Natl. Acad. Sci. USA* 1978;75(2):871–875. [PubMed: 204938]
52. FREED LE, VUNJAK-NOVAKOVIC G, BIRON RJ, et al. Biodegradable polymer scaffolds for tissue engineering. *Biotechnology (NY)* 1994;12(7):689–693.
53. BELL E, IVARSSON B, MERRILL C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. *Proc. Natl. Acad. Sci. USA* 1979;76(3):1274–1278. [PubMed: 286310]
54. VAN HEST JC, TIRRELL DA. Protein-based materials, toward a new level of structural control. *Chem. Commun. (Camb.)* 2001;19:1897–1904. [PubMed: 12240211]
55. MURPHY WL, SIMMONS CA, KAIGLER D, MOONEY DJ. Bone regeneration via a mineral substrate and induced angiogenesis. *J. Dent Res* 2004;83(3):204–210. [PubMed: 14981120]
56. CHANG SC, ROWLEY JA, TOBIAS G, et al. Injection molding of chondrocyte/alginate constructs in the shape of facial implants. *J. Biomed. Mater. Res* 2001;55(4):503–511. [PubMed: 11288078]
57. HALBERSTADT C, AUSTIN C, ROWLEY J, et al. A hydrogel material for plastic and reconstructive applications injected into the subcutaneous space of a sheep. *Tissue Eng* 2002;8(2):309–319. [PubMed: 12031119]
58. ALSBERG E, HILL EE, MOONEY DJ. Craniofacial tissue engineering. *Crit. Rev. Oral Biol. Med* 2001;12(1):64–75. [PubMed: 11349963]
59. SHAKESHEFF K, CANNIZZARO S, LANGER R. Creating biomimetic micro-environments with synthetic polymer-peptide hybrid molecules. *J. Biomater. Sci. Polym. Ed* 1998;9(5):507–518. [PubMed: 9648030]
60. ROWLEY JA, MADLAMBAYAN G, MOONEY DJ. Alginate hydrogels as synthetic extracellular matrix materials. *Biomaterials* 1999;20(1):45–53. [PubMed: 9916770]
61. LENDLEIN A, LANGER R. Biodegradable, elastic shape-memory polymers for potential biomedical applications. *Science* 2002;296(5573):1673–1676. [PubMed: 11976407]
62. THORNTON AJ, ALSBERG E, ALBERTELLI M, MOONEY DJ. Shape-defining scaffolds for minimally invasive tissue engineering. *Transplantation* 2004;77(12):1798–1803. [PubMed: 15360280]

15223894]An important consideration for the use of biomaterials as vehicles for delivery of DNA, growth factors and cells is not just how the biomaterial will enable the delivery of the desired signal, but how the biomaterial itself will be delivered. This study represents a mechanism by which shaped hydrogels, formed by covalently cross-linking, can be structurally collapsed into smaller, temporary shapes that permit their minimally invasive delivery *in vivo*.

63. STAYTON PS, EL-SAYED ME, MURTHY N, et al. 'Smart' delivery systems for biomolecular therapeutics. *Orthod. Craniofac. Res* 2005;8(3):219–225. [PubMed: 16022724]The microenvironment into which biological signals are released and the ability of these signals to reach intracellular targets are key determinants of the ultimate effects of the delivered signals. The key feature of the polymers examined in this study is their ability to directly enhance the intracellular delivery of proteins and DNA, by destabilising biological membranes in response to vesicular compartment pH changes.
64. AGULNIK M, SIU LL. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents. *Curr. Med. Chem. Anticancer Agents* 2004;4(6): 543–551. [PubMed: 15579019]
65. TZIAFAS D. The future role of a molecular approach to pulp-dentinal regeneration. *Caries Res* 2004;38(3):314–320. [PubMed: 15153705]
66. SMITH AJ. Vitality of the dentin-pulp complex in health and disease: growth factors as key mediators. *J. Dent. Educ* 2003;67(6):678–689. [PubMed: 12856968]
67. NAKASHIMA M, TACHIBANA K, IOHARA K, et al. Induction of reparative dentin formation by ultrasound-mediated gene delivery of growth/differentiation factor 11. *Hum. Gene Ther* 2003;14(6): 591–597. [PubMed: 12718768]
68. NISHIMURA F, TERRANOVA VP. Comparative study of the chemotactic responses of periodontal ligament cells and gingival fibroblasts to polypeptide growth factors. *J. Dent. Res* 1996;75(4):986–992. [PubMed: 8708140]
69. SAYGIN NE, TOKIYASU Y, GIANNOBILE WV, SOMERMAN MJ. Growth factors regulate expression of mineral associated genes in cementoblasts. *J. Periodontol* 2000;71(10):1591–1600. [PubMed: 11063392]
70. STRAYHORN CL, GARRETT JS, DUNN RL, BENEDICT JJ, SOMERMAN MJ. Growth factors regulate expression of osteoblast-associated genes. *J. Periodontol* 1999;70(11):1345–1354. [PubMed: 10588498]
71. CANALIS E. Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat calvaria. *Metabolism* 1981;30(10):970–975. [PubMed: 7024723]
72. BARTOLD PM, RABEN A. Growth factor modulation of fibroblasts in simulated wound healing. *J. Periodontal Res* 1996;31(3):205–216. [PubMed: 8926571]
73. OJIMA Y, MIZUNO M, KUBOKI Y, KOMORI T. *In vitro* effect of platelet-derived growth factor-BB on collagen synthesis and proliferation of human periodontal ligament cells. *Oral Dis* 2003;9(3): 144–151. [PubMed: 12945596]
74. REIGSTAD LJ, VARHAUG JE, LILLEHAUG JR. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. *FEBS J* 2005;272 (22):5723–5741. [PubMed: 16279938]
75. BOYAN LA, BHARGAVA G, NISHIMURA F, et al. Mitogenic and chemotactic responses of human periodontal ligament cells to the different isoforms of platelet-derived growth factor. *J. Dent. Res* 1994;73(10):1593–1600. [PubMed: 7929973]
76. MATSUDA N, LIN WL, KUMAR NM, CHO MI, GENCO RJ. Mitogenic, chemotactic, and synthetic responses of rat periodontal ligament fibroblastic cells to polypeptide growth factors *in vitro*. *J. Periodontol* 1992;63(6):515–525. [PubMed: 1625151]
77. LYNCH SE, BUSER D, HERNANDEZ RA, et al. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs. *J. Periodontol* 1991;62(11):710–716. [PubMed: 1753324]
78. LYNCH SE, DE CASTILLA GR, WILLIAMS RC, et al. The effects of short-term application of a combination of platelet-derived and insulin-like growth factors on periodontal wound healing. *J. Periodontol* 1991;62(7):458–467. [PubMed: 1920013]

79. LYNCH SE, WILLIAMS RC, POLSON AM, et al. A combination of platelet-derived and insulin-like growth factors enhances periodontal regeneration. *J. Clin. Periodontol* 1989;16(8):545–548. [PubMed: 2778088]
80. GIANNOBILE WV, FINKELMAN RD, LYNCH SE. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. *J. Periodontol* 1994;65(12):1158–1168. [PubMed: 7877089]
81. GIANNOBILE WV, HERNANDEZ RA, FINKELMAN RD, et al. Comparative effects of platelet-derived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in *Macaca fascicularis*. *J. Periodontal Res* 1996;31(5):301–312. [PubMed: 8858534]
82. STEFANI CM, MACHADO MA, SALLUM EA, et al. Platelet-derived growth factor/insulin-like growth factor-I combination and bone regeneration around implants placed into extraction sockets: a histometric study in dogs. *Implant. Dent* 2000;9(2):126–131. [PubMed: 11314699]
83. HOWELL TH, FIORELLINI JP, PAQUETTE DW, et al. A Phase I/II clinical trial to evaluate a combination of recombinant human platelet-derived growth factor-BB and recombinant human insulin-like growth factor-I in patients with periodontal disease. *J. Periodontol* 1997;68(12):1186–1193. [PubMed: 9444594]
84. PARK JB, MATSUURA M, HAN KY, et al. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. *J. Periodontol* 1995;66(6):462–477. [PubMed: 7562336]
85. CHO MI, LIN WL, GENCO RJ. Platelet-derived growth factor-modulated guided tissue regenerative therapy. *J. Periodontol* 1995;66(6):522–530. [PubMed: 7562342]
86. WANG HL, PAPPERT TD, CASTELLI WA, et al. The effect of platelet-derived growth factor on the cellular response of the periodontium: an autoradiographic study on dogs. *J. Periodontol* 1994;65(5):429–436. [PubMed: 8046558]
87. CAMELO M, NEVINS ML, SCHENK RK, LYNCH SE, NEVINS M. Periodontal regeneration in human class II furcations using purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) with bone allograft. *Int. J. Periodontics Restorative Dent* 2003;23(3):213–225. [PubMed: 12854772]
88. NEVINS M, CAMELO M, NEVINS ML, SCHENK RK, LYNCH SE. Periodontal regeneration in humans using recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and allogenic bone. *J. Periodontol* 2003;74(9):1282–1292. [PubMed: 14584860]
89. NEVINS M, GIANNOBILE WV, MCGUIRE MK, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. *J. Periodontol* 2005;76(12):2205–2215. [PubMed: 16332231] This large-scale clinical trial evaluated the effect of a locally delivered recombinant growth factor (PDGF) on periodontal regeneration. It demonstrated that PDGF delivered with a β -tricalcium phosphate carrier significantly enhanced bone fill and attachment level gain when compared with vehicle control conditions. The study is highly significant in that it is the largest prospective, randomised, triple-blinded, and controlled clinical trial assessing a putative periodontal regenerative and wound-healing therapy employing a growth factor.
90. TAKAYAMA S, MURAKAMI S, MIKI Y, et al. Effects of basic fibroblast growth factor on human periodontal ligament cells. *J. Periodontal Res* 1997;32(8):667–675. [PubMed: 9409462]
91. TERRANOVA VP, ODZIEMIEC C, TWEDEN KS, SPADONE DP. Repopulation of dentin surfaces by periodontal ligament cells and endothelial cells. Effect of basic fibroblast growth factor. *J. Periodontol* 1989;60(6):293–301. [PubMed: 2550605]
92. ROSSA C JR, MARCANTONIO E Jr, CIRELLI JA, et al. Regeneration of class III furcation defects with basic fibroblast growth factor (b-FGF) associated with GTR. A descriptive and histometric study in dogs. *J. Periodontol* 2000;71(5):775–784. [PubMed: 10872959]
93. MURAKAMI S, TAKAYAMA S, KITAMURA M, et al. Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. *J. Periodontal Res* 2003;38(1):97–103. [PubMed: 12558943]
94. NAKAHARA T, NAKAMURA T, KOBAYASHI E, et al. Novel approach to regeneration of periodontal tissues based on in situ tissue engineering: effects of controlled release of basic fibroblast growth factor from a sandwich membrane. *Tissue Eng* 2003;9(1):153–162. [PubMed: 12625964]

95. SATO Y, KIKUCHI M, OHATA N, TAMURA M, KUBOKI Y. Enhanced cementum formation in experimentally induced cementum defects of the root surface with the application of recombinant basic fibroblast growth factor in collagen gel *in vivo*. *J. Periodontol* 2004;75(2):243–248. [PubMed: 15068112]
96. TAKAYAMA S, MURAKAMI S, SHIMABUKURO Y, KITAMURA M, OKADA H. Periodontal regeneration by FGF-2 (bFGF) in primate models. *J. Dent. Res* 2001;80(12):2075–2079. [PubMed: 11808765]
97. CLOKIE CM, BELL RC. Recombinant human transforming growth factor β -1 and its effects on osseointegration. *J. Craniofac. Surg* 2003;14(3):268–277. [PubMed: 12826796]
98. TATAKIS DN, WIKESJO UM, RAZI SS, et al. Periodontal repair in dogs: effect of transforming growth factor- β 1 on alveolar bone and cementum regeneration. *J. Clin. Periodontol* 2000;27(9):698–704. [PubMed: 10983604]
99. WIKESJO UM, RAZI SS, SIGURDSSON TJ, et al. Periodontal repair in dogs: effect of recombinant human transforming growth factor- β 1 on guided tissue regeneration. *J. Clin. Periodontol* 1998;25(6):475–481. [PubMed: 9667481]
100. MOHAMMED S, PACK AR, KARDOS TB. The effect of transforming growth factor- β 1 (TGF- β 1) on wound healing, with or without barrier membranes, in a class II furcation defect in sheep. *J. Periodontol Res* 1998;33(6):335–344. [PubMed: 9777584]
101. SIGURDSSON TJ, LEE MB, KUBOTA K, et al. Periodontal repair in dogs: recombinant human bone morphogenetic protein-2 significantly enhances periodontal regeneration. *J. Periodontol* 1995;66(2):131–138. [PubMed: 7730964]
102. WIKESJO UM, XIROPAIDIS AV, THOMSON RC, et al. Periodontal repair in dogs: space-providing ePTFE devices increase rhBMP-2/ACS-induced bone formation. *J. Clin. Periodontol* 2003;30(8):715–725. [PubMed: 12887340]
103. SORENSEN RG, WIKESJO UM, KINOSHITA A, WOZNEY JM. Periodontal repair in dogs: evaluation of a bioresorbable calcium phosphate cement (Ceredex) as a carrier for rhBMP-2. *J. Clin. Periodontol* 2004;31(9):796–804. [PubMed: 15312104]
104. CHOI SH, KIM CK, CHO KS, et al. Effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) on healing in 3-wall intrabony defects in dogs. *J. Periodontol* 2002;73(1):63–72. [PubMed: 11852905]
105. KING GN, KING N, CRUCHLEY AT, WOZNEY JM, HUGHES FJ. Recombinant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. *J. Dent. Res* 1997;76(8):1460–1470. [PubMed: 9240382]
106. HIGUCHI T, KINOSHITA A, TAKAHASHI K, ODA S, ISHIKAWA I. Bone regeneration by recombinant human bone morphogenetic protein-2 in rat mandibular defects. An experimental model of defect filling. *J. Periodontol* 1999;70(9):1026–1031. [PubMed: 10505805]
107. WIKESJO UM, XIROPAIDIS AV, THOMSON RC, et al. Periodontal repair in dogs: rhBMP-2 significantly enhances bone formation under provisions for guided tissue regeneration. *J. Clin. Periodontol* 2003;30(8):705–714. [PubMed: 12887339]
108. WIKESJO UM, LIM WH, THOMSON RC, et al. Periodontal repair in dogs: evaluation of a bioabsorbable space-providing macroporous membrane with recombinant human bone morphogenetic protein-2. *J. Periodontol* 2003;74(5):635–647. [PubMed: 12816296]
109. WIKESJO UM, GUGLIELMONI P, PROMSUDTHI A, et al. Periodontal repair in dogs: effect of rhBMP-2 concentration on regeneration of alveolar bone and periodontal attachment. *J. Clin. Periodontol* 1999;26(6):392–400. [PubMed: 10382580]
110. TAKAHASHI D, ODAJIMA T, MORITA M, KAWANAMI M, KATO H. Formation and resolution of ankylosis under application of recombinant human bone morphogenetic protein-2 (rhBMP-2) to class III furcation defects in cats. *J. Periodontol Res* 2005;40(4):299–305. [PubMed: 15966907]
111. WIKESJO UM, QAHASH M, THOMSON RC, et al. rhBMP-2 significantly enhances guided bone regeneration. *Clin. Oral Implants Res* 2004;15(2):194–204. [PubMed: 15008931]
112. HANISCH O, SORENSEN RG, KINOSHITA A, et al. Effect of recombinant human bone morphogenetic protein-2 in dehiscence defects with non-submerged immediate implants: an experimental study in Cynomolgus monkeys. *J. Periodontol* 2003;74(5):648–657. [PubMed: 12816297]

113. HANISCH O, TATAKIS DN, BOSKOVIC MM, ROHRER MD, WIKESJO UM. Bone formation and reosseointegration in peri-implantitis defects following surgical implantation of rhBMP-2. *Int. J. Oral Maxillofac. Implants* 1997;12(5):604–610. [PubMed: 9337020]
114. HANISCH O, TATAKIS DN, ROHRER MD, et al. Bone formation and osseointegration stimulated by rhBMP-2 following subantral augmentation procedures in nonhuman primates. *Int. J. Oral Maxillofac. Implants* 1997;12(6):785–792. [PubMed: 9425759]
115. WIKESJO UM, SORENSEN RG, WOZNEY JM. Augmentation of alveolar bone and dental implant osseointegration: clinical implications of studies with rhBMP-2. *J. Bone Joint Surg. Am* 2001;83-A(Suppl 1 Pt 2):S136–S145. [PubMed: 11314791]
116. BARBOZA EP, CAULA AL, CAULA FDE O, et al. Effect of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge with space-providing biomaterials on the augmentation of chronic alveolar ridge defects. *J. Periodontol* 2004;75(5):702–708. [PubMed: 15212353]
117. BOYNE PJ, MARX RE, NEVINS M, et al. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. *Int. J. Periodontics Restorative Dent* 1997;17(1):11–25. [PubMed: 10332250]
118. JUNG RE, GLAUSER R, SCHARER P, et al. Effect of rhBMP-2 on guided bone regeneration in humans. *Clin. Oral Implants Res* 2003;14(5):556–568. [PubMed: 12969359] This split-mouth design clinical study examined the effects of a rhBMP-2 on bone regeneration when added exogenously to a xenogeneic bone graft material in guided bone regenerative procedures. The significance of this paper is the finding that the combination of the xenogenic bone substitute mineral with rhBMP-2 can enhance the maturation process of bone regeneration and can increase the graft-to-bone contact in humans.
119. HOWELL TH, FIORELLINI J, JONES A, et al. A feasibility study evaluating rhBMP-2/absorbable collagen sponge device for local alveolar ridge preservation or augmentation. *Int. J. Periodontics Restorative Dent* 1997;17(2):124–139. [PubMed: 9497707]
120. BOYNE PJ, LILLY LC, MARX RE, et al. *De novo* bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. *J. Oral Maxillofac. Surg* 2005;63(12):1693–1707. [PubMed: 16297689] Sinus floor augmentation is often necessary prior to implant therapy in order to regenerate enough bone to stably place and support dental implants. The ability of rhBMP-2 to regenerate bone in these procedures was evaluated in comparison to conventional bone-grafting techniques. This is an important study in that it is the first randomised controlled clinical trial demonstrating *de novo* bone regeneration from a recombinant human protein. It also demonstrated that the quality of rhBMP-2 regenerated bone was comparable to bone regenerated from conventional procedures.
121. GIANNOBILE WV, RYAN S, SHIH MS, et al. Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in class III furcation defects. *J. Periodontol* 1998;69(2):129–137. [PubMed: 9526911]
122. RIPAMONTI U, CROOKS J, PETIT JC, RUEGER DC. Periodontal tissue regeneration by combined applications of recombinant human osteogenic protein-1 and bone morphogenetic protein-2. A pilot study in Chacma baboons (*Papio ursinus*). *Eur. J. Oral Sci* 2001;109(4):241–248. [PubMed: 11531070]
123. RIPAMONTI U, HELIOTIS M, RUEGER DC, SAMPATH TK. Induction of cementogenesis by recombinant human osteogenic protein-1 (hop-1/bmp-7) in the baboon (*Papio ursinus*). *Arch. Oral Biol* 1996;41(1):121–126. [PubMed: 8833601]
124. COOK SD, SALKELD SL, RUEGER DC. Evaluation of recombinant human osteogenic protein-1 (rhOP-1) placed with dental implants in fresh extraction sites. *J. Oral Implantol* 1995;21(4):281–289. [PubMed: 8699520]
125. ZHANG R, AN Y, TOTH CA, et al. Osteogenic protein-1 enhances osseointegration of titanium implants coated with peri-apatite in rabbit femoral defect. *J. Biomed Mater. Res. B Appl. Biomater* 2004;71(2):408–413. [PubMed: 15389505]
126. MARGOLIN MD, COGAN AG, TAYLOR M, et al. Maxillary sinus augmentation in the non-human primate: a comparative radiographic and histologic study between recombinant human osteogenic protein-1 and natural bone mineral. *J. Periodontol* 1998;69(8):911–919. [PubMed: 9736374]

127. VAN DEN BERGH JP, TEN BRUGGENKATE CM, GROENEVELD HH, BURGER EH, TUINZING DB. Recombinant human bone morphogenetic protein-7 in maxillary sinus floor elevation surgery in 3 patients compared to autogenous bone grafts. A clinical pilot study. *J. Clin. Periodontol* 2000;27(9):627–636. [PubMed: 10983596]
128. WOLFMAN NM, HATTERSLEY G, COX K, et al. Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF- β gene family. *J. Clin. Invest* 1997;100(2):321–330. [PubMed: 9218508]
129. WIKESJO UM, SORENSEN RG, KINOSHITA A, JIAN LI X, WOZNEY JM. Periodontal repair in dogs: effect of recombinant human bone morphogenetic protein-12 (rhBMP-12) on regeneration of alveolar bone and periodontal attachment. *J. Clin. Periodontol* 2004;31(8):662–670. [PubMed: 15257745]
130. HAMMARSTROM L. Enamel matrix, cementum development and regeneration. *J. Clin. Periodontol* 1997;24(9 Pt 2):658–668. [PubMed: 9310870]
131. HAMMARSTROM L, HEIJL L, GESTRELIUS S. Periodontal regeneration in a buccal dehiscence model in monkeys after application of enamel matrix proteins. *J. Clin. Periodontol* 1997;24(9 Pt 2):669–677. [PubMed: 9310871]
132. GIANNOBILE WV, AL-SHAMMARI KF, SARMENT DP. Matrix molecules and growth factors as indicators of periodontal disease activity. *Periodontol.* 2000 2003;31:125–134. [PubMed: 12656999]
133. VENEZIA E, GOLDSTEIN M, BOYAN BD, SCHWARTZ Z. The use of enamel matrix derivative in the treatment of periodontal defects: a literature review and meta-analysis. *Crit. Rev. Oral Biol. Med* 2004;15(6):382–402. [PubMed: 15574680]
134. ESPOSITO M, GRUSOVIN MG, COULTHARD P, WORTHINGTON HV. Enamel matrix derivative (Emdogain) for periodontal tissue regeneration in intrabony defects. *Cochrane Database Syst. Rev* 2005;4CD003875
135. ANUSAKSATHIEN, O.; JIN, Q.; MA, PX.; GIANNOBILE, WV. Scaffolding in periodontal engineering. In: Ma, PX.; Elisseeff, J., editors. *Scaffolding in Tissue Engineering*. CRC Press; Boca Raton, FL, USA: 2006. p. 437-454.
136. MURPHY WL, PETERS MC, KOHN DH, MOONEY DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. *Biomaterials* 2000;21(24):2521–2527. [PubMed: 11071602]
137. WEI G, JIN Q, GIANNOBILE WV, MA PX. Nanofibrous scaffold for controlled delivery of recombinant human PDGF-BB. *J. Control. Release* 2006;112(1):103–110. [PubMed: 16516328]
138. CHANG SC, WEI FC, CHUANG H, et al. *Ex vivo* gene therapy in autologous critical-size craniofacial bone regeneration. *Plast. Reconstr. Surg* 2003;112(7):1841–1850. [PubMed: 14663228]
139. BAUM BJ, O'CONNELL BC. *In vivo* gene transfer to salivary glands. *Crit. Rev. Oral Biol. Med* 1999;10(3):276–283. [PubMed: 10759409]
140. DELPORTE C, O'CONNELL BC, HE X, et al. Increased fluid secretion after adenoviral-mediated transfer of the aquaporin-1 cDNA to irradiated rat salivary glands. *Proc. Natl. Acad. Sci. USA* 1997;94(7):3268–3273. [PubMed: 9096382] Adenoviral mediated gene transfer was examined in this study to evaluate the functional potential of gene delivery on salivary glands, which were hypofunctional as a result of radiation treatment. Gene therapy led to a two- to threefold increase in salivary secretion compared with secretion from glands that were administered a control virus. This study is significant in that it is one of the earliest studies to demonstrate a successful functional response using a gene therapy approach to treat a hypofunctional organ.
141. HENDRIE PC, RUSSELL DW. Gene targeting with viral vectors. *Mol. Ther* 2005;12(1):9–17. [PubMed: 15932801]
142. RAMSEIER CA, ABRAMSON Z, JIN Q, GIANNOBILE W. Gene therapy for periodontal regenerative medicine. *Dent. Clin. N. Amer* 2006;50(2):245–263. [PubMed: 16530061]
143. WORGALL S. A realistic chance for gene therapy in the near future. *Pediatr. Nephrol* 2005;20(2): 118–124. [PubMed: 15549408]

144. ZHU Z, LEE CS, TEJEDA KM, GIANNOBILE WV. Gene transfer and expression of platelet-derived growth factors modulate periodontal cellular activity. *J. Dent. Res* 2001;80(3):892–897. [PubMed: 11379891]
145. THOMAS CE, EHRHARDT A, KAY MA. Progress and problems with the use of viral vectors for gene therapy. *Nat. Rev. Genet* 2003;4(5):346–358. [PubMed: 12728277]
146. GARDLIK R, PALFFY R, HODOSY J, et al. Vectors and delivery systems in gene therapy. *Med. Sci. Monit* 2005;11(4):RA110–RA121. [PubMed: 15795707]
147. SCHMIDT-WOLF GD, SCHMIDT-WOLF IG. Non-viral and hybrid vectors in human gene therapy: an update. *Trends Mol. Med* 2003;9(2):67–72. [PubMed: 12615040]
148. LATTANZI W, POLA E, PECORINI G, LOGROSCINO CA, ROBBINS PD. Gene therapy for *in vivo* bone formation: recent advances. *Eur. Rev. Med. Pharmacol. Sci* 2005;9(3):167–174. [PubMed: 16080636]
149. GIANNOBILE WV, LEE CS, TOMALA MP, TEJEDA KM, ZHU Z. Platelet-derived growth factor (PDGF) gene delivery for application in periodontal tissue engineering. *J. Periodontol* 2001;72(6):815–823. [PubMed: 11453245]
150. CHEN QP, GIANNOBILE WV. Adenoviral gene transfer of PDGF downregulates gas gene product PDGF α R and prolongs ERK and Akt/PKB activation. *Am. J. Physiol. Cell Physiol* 2002;282(3):C538–C544. [PubMed: 11832339]
151. JIN QM, ANUSAKSATHIEN O, WEBB SA, RUTHERFORD RB, GIANNOBILE WV. Gene therapy of bone morphogenetic protein for periodontal tissue engineering. *J. Periodontol* 2003;74(2):202–213. [PubMed: 12666709]
152. JIN Q, ANUSAKSATHIEN O, WEBB SA, PRINTZ MA, GIANNOBILE WV. Engineering of tooth-supporting structures by delivery of PDGF gene therapy vectors. *Mol. Ther* 2004;9(4):519–526. [PubMed: 15093182]
153. DUNN CA, JIN Q, TABA M Jr, et al. BMP gene delivery for alveolar bone engineering at dental implant defects. *Mol. Ther* 2005;11(2):294–299. [PubMed: 15668141] This study evaluates the bone regenerative potential of *in vivo* gene delivery of Ad/BMP-7 around dental implants. The significance of this study is that it demonstrated targeted sustained transgene expression (up to 10 days) and that treatment of dental implant fixtures with Ad/BMP-7 could result in enhancements of alveolar bone defect fill, bone formation and bone-to-implant contact.
154. GAILIT J, CLARK RA. Wound repair in the context of extracellular matrix. *Curr. Opin. Cell Biol* 1994;6(5):717–725. [PubMed: 7530463]
155. SINGER AJ, CLARK RA. Cutaneous wound healing. *N. Engl. J. Med* 1999;341(10):738–746. [PubMed: 10471461]
156. CLARK RA. Wound repair. *Curr. Opin. Cell Biol* 1989;1(5):1000–1008. [PubMed: 2697286]
157. SELVIG KA, SORENSEN RG, WOZNEY JM, WIKESJO UM. Bone repair following recombinant human bone morphogenetic protein-2 stimulated periodontal regeneration. *J. Periodontol* 2002;73(9):1020–1029. [PubMed: 12296587]
158. SIGURDSSON TJ, NYGAARD L, TATAKIS DN, et al. Periodontal repair in dogs: evaluation of rhBMP-2 carriers. *Int. J. Periodontics Restorative Dent* 1996;16(6):524–537. [PubMed: 9242091]
159. KINOSHITA A, ODA S, TAKAHASHI K, YOKOTA S, ISHIKAWA I. Periodontal regeneration by application of recombinant human bone morphogenetic protein-2 to horizontal circumferential defects created by experimental periodontitis in beagle dogs. *J. Periodontol* 1997;68(2):103–109. [PubMed: 9058326]
160. ZELLIN G, LINDE A. Importance of delivery systems for growth-stimulatory factors in combination with osteopromotive membranes. An experimental study using rhBMP-2 in rat mandibular defects. *J. Biomed. Mater. Res* 1997;35(2):181–190. [PubMed: 9135167]
161. NEVINS M, KIRKER-HEAD C, WOZNEY JA, PALMER R, GRAHAM D. Bone formation in the goat maxillary sinus induced by absorbable collagen sponge implants impregnated with recombinant human bone morphogenetic protein-2. *Int. J. Periodontics Restorative Dent* 1996;16(1):8–19. [PubMed: 8631615]
162. LINDSEY WH. Osseous tissue engineering with gene therapy for facial bone reconstruction. *Laryngoscope* 2001;111(7):1128–1136. [PubMed: 11568532]

163. ALDEN TD, BERES EJ, LAURENT JS, et al. The use of bone morphogenetic protein gene therapy in craniofacial bone repair. *J. Craniofac. Surg* 2000;11(1):24–30. [PubMed: 11314095]
164. MACK CA, MAGOVERN CJ, BUDENBENDER KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. *J. Vasc. Surg* 1998;27(4):699–709. [PubMed: 9576084]
165. KREBSBACH PH, GU K, FRANCESCHI RT, RUTHERFORD RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone *in vivo*. *Hum. Gene Ther* 2000;11(8):1201–1210. [PubMed: 10834621]
166. PENG H, WRIGHT V, USAS A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. *J. Clin. Invest* 2002;110(6):751–759. [PubMed: 12235106]
167. ZHENG C, HOQUE AT, BRADDON VR, BAUM BJ, O'CONNELL BC. Evaluation of salivary gland acinar and ductal cell-specific promoters *in vivo* with recombinant adenoviral vectors. *Hum. Gene Ther* 2001;12(18):2215–2223. [PubMed: 11779405]
168. YAMANO S, ATKINSON JC, BAUM BJ, FOX PC. Salivary gland cytokine expression in NOD and normal BALB/c mice. *Clin. Immunol* 1999;92(3):265–275. [PubMed: 10479531]
169. YAMANO S, SCOTT DE, HUANG LY, et al. Protection from experimental endotoxemia by a recombinant adeno-associated virus encoding interleukin 10. *J. Gene Med* 2001;3(5):450–457. [PubMed: 11601758]
170. VITOLO JM, BAUM BJ. The use of gene transfer for the protection and repair of salivary glands. *Oral Dis* 2002;8(4):183–191. [PubMed: 12206399]
171. NAKASHIMA M, IOHARA K, ISHIKAWA M, et al. Stimulation of reparative dentin formation by *ex vivo* gene therapy using dental pulp stem cells electrotransfected with growth/differentiation factor 11 (Gdf11). *Hum. Gene Ther* 2004;15(11):1045–1053. [PubMed: 15610605]
172. NAKASHIMA M, MIZUNUMA K, MURAKAMI T, AKAMINE A. Induction of dental pulp stem cell differentiation into odontoblasts by electroporation-mediated gene delivery of growth/differentiation factor 11 (Gdf11). *Gene Ther* 2002;9(12):814–818. [PubMed: 12040463]
173. RUTHERFORD RB. BMP-7 gene transfer to inflamed ferret dental pulps. *Eur. J. Oral Sci* 2001;109(6):422–424. [PubMed: 11767280]
174. KUBOKI T, NAKANISHI T, KANYAMA M, et al. Direct adenovirus-mediated gene delivery to the temporomandibular joint in guinea-pigs. *Arch. Oral Biol* 1999;44(9):701–709. [PubMed: 10471154]
175. ANUSAKSATHIEN O, JIN Q, ZHAO M, SOMERMAN MJ, GIANNOBILE WV. Effect of sustained gene delivery of platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum. *J. Periodontol* 2004;75(3):429–440. [PubMed: 15088882] Cementum is a key structure in the periodontal attachment apparatus and short-term administration of PDGF has been shown to partially regenerate periodontal structures and play a role in cementogenesis. Using an *ex vivo* ectopic biomineralisation model, the aim of this study was to determine the effect of sustained PDGF gene transfer on cementum formation. The significance of the study is in the findings, which suggest that continuous exogenous delivery of PDGF-A may actually delay mineral formation induced by cementoblasts, potentially through an inhibitory mechanism involving osteopontin.

Figure 1. Gene therapy approaches

A. DNA and growth factors can be delivered to cells through different mechanisms, including direct injection to an *in vivo* site, transport to a site via a carrier matrix, or introduced *ex vivo* prior to cell transplantation. **B.** Genetic material can be transferred into cells using different vectors, the most common of which are plasmids, retroviruses, adenoviruses and adeno-associated viruses. **C.** Growth factor delivery by gene therapy strategies aim to modulate cell proliferation, migration, matrix synthesis and differentiation.

Figure 2. Specific examples of different strategies for tissue engineering craniofacial tissues

A. Growth factor delivery via an injectable system to stimulate regeneration of the cartilaginous articular disc of the temporomandibular joint. **B.** Cell transplantation of salivary gland cells on polymer scaffolds to restore a functionally deficient salivary gland. **C.** Combined approach of cell transplantation and growth factor delivery for bone regeneration using a growth factor-releasing scaffold as a cell carrier for osteo-progenitor cells. **D.** Gene therapy approach employed to regenerate the periodontium of a periodontal defect resulting from periodontal disease. **E.** Cell therapy approach using bone precursor cells as an autogenous bone graft to enable the placement of dental implants in an area that is commonly deficient in bone (below the maxillary sinus).

Table 1

Effects of growth factors in the different phases of wound healing.

Wound-healing phase	Growth factor	Cell of origin	Functions
Inflammatory	PDGF TGF- β	Platelets Platelets leukocytes, fibroblasts	Increases chemotaxis of neutrophils and monocytes Increases chemotaxis of neutrophils and monocytes Autocrine expression: generation of additional cytokines (TNF- α , IL-1 β , PDGF and chemokines)
Proliferative	VEGF EGF	Platelets, leukocytes, fibroblasts Macrophages, mesenchymal cells, platelets	Increases vascular permeability Stimulates epithelial proliferation and migration
	FGF-2	Macrophages, endothelial cells	Stimulates fibroblasts proliferation and ECM synthesis Increases chemotaxis, proliferation and differentiation of endothelial cells
	KGF (FGF-7) PDGF	Keratinocytes, fibroblasts Macrophages, endothelial cells	Stimulates epithelial proliferation and migration Stimulates fibroblast proliferation and ECM synthesis Increases chemotaxis, proliferation and differentiation of endothelial cells
	TGF- β	Macrophages, leukocytes, fibroblasts	Stimulates epithelial proliferation and migration Stimulates fibroblasts proliferation and ECM synthesis Inhibits proteases and enhances inhibitor production
	VEGF	Macrophages	Increases chemotaxis of endothelial progenitor cells Stimulates endothelial cell proliferation Stimulates mesenchymal progenitor cell migration
Bone remodelling matrix synthesis	BMPs 2 – 4	Osteoblasts	
	BMP-7 FGF-2 IGF-2	Osteoblasts Macrophages, endothelial cells Macrophages, fibroblasts	Stimulates osteoblast and chondroblast differentiation Stimulates mesenchymal progenitor cell migration Stimulates osteoblast proliferation and bone matrix synthesis
	PDGF	Macrophages	Stimulates differentiation of fibroblasts into myofibroblasts Stimulates proliferation of mesenchymal progenitor cells
	TGF- β	Fibroblasts, osteoblasts	Induces endothelial cell and fibroblast apoptosis Induces differentiation of fibroblasts into myofibroblasts
	VEGF	Macrophages	Stimulates chemotaxis and survival of osteoblasts Chemotaxis of mesenchymal stem cells, antiapoptotic effect on the bone-forming cells, angiogenesis promotion

BMP: Bone morphogenetic protein; ECM: Extracellular matrix; EGF: Epidermal growth factor; FGF: Fibroblast growth factor; IGF: Insulin-like growth factor; KGF: Keratinocyte growth factor; PDGF: Platelet-derived growth factor; TGF: Transforming growth factor; VEGF: Vascular endothelial growth factor.

Information from [11,154-156].

Table 2

Preclinical and clinical studies using growth factors in oral and periodontal healing.

Growth factor	Pre-clinical studies	Clinical studies
BMP-2	Periodontal defects: stimulated alveolar bone regeneration [17,101,103-105,107-110,157-159] Mandibular bone defects: induced new bone growth [106,116,160] Sinus floor: stimulated bone augmentation [114,161] Peri-implant defects: stimulated bone regeneration [106,111-113,115] Dentin–pulp complex: stimulation of dentin regeneration [65]	Alveolar bone: induced bone ridge augmentation [119] Sinus floor: induced bone formation [117,120] Peri-implant bone defects: accelerated bone regeneration [118]
BMP-7	Periodontal furcation defects: stimulated significant cementum and bone regeneration [121-123] Peri-implant defects: stimulated bone regeneration [124,125] Sinus floor: similar to bone grafts in bone augmentation [126] Dentin–pulp complex: stimulation of dentin regeneration [65]	Sinus floor augmentation: variable amount of bone regeneration after implantation in three patients [127]
BMP-12	Periodontal defects: new PDL with improved fibre orientation when compared with BMP-2 [129]	
FGF-2	Furcation and intrabony periodontal defects: improved periodontal regeneration (new bone, cementum and PDL) [92-95]	
PDGF	Periodontal furcation and fenestration defects: accelerated healing and improved PDL and bone regeneration [84-86]	Furcation and intrabony defects: histological evidence of periodontal regeneration in proof-of-principle studies [87,88]; improved clinical attachment level gain and radiographic bone filling [89]
PDGF plus IGF	Periodontal defects: improved periodontal regeneration (new bone, cementum and PDL) [78-81] Peri-implant defects: improved bone regeneration [77,82]	Periodontal defects: improved bone growth and filling of defects [83]
TGF- β	Periodontal defects: insignificant improvement in cementum formation; conflicting results regarding alveolar bone regeneration [98-100] Dentin–pulp complex: results for dentin regeneration [65]	

BMP: Bone morphogenetic protein; FGF: Fibroblast growth factor; IGF: Insulin-like growth factor; PDGF: Platelet-derived growth factor; PDL: Periodontal ligament; TGF: Transforming growth factor.

Table 3

Gene therapy studies for craniofacial applications.

Tissue	Vector	Purpose	Ref.
Cranium	Ad-BMP-2	Bone regeneration (craniofacial defects)	[138,162]
	Ad-BMP-2 and -9	Bone regeneration (mandible)	[163]
	Ad-VEGF	Angiogenesis: tissue ischaemia	[164]
	Ad-BMP-7	Repair of skull defects	[165]
	Retro-BMP-4 plus VEGF	Repair of skull defects	[166]
Salivary gland	Ad-aquaporin-1 (Ad-AQP1)	Stimulate salivary secretion	[139,140,167]
	AAV-IL-10	Autoimmune epithelialitis (Sjögren's syndrome)	[168,169]
	Liposome/plasmid complex: 'gene cocktail'	Reduce levels of superoxide radicals and hydrogen peroxide (protection against irradiation damage)	[170]
		Stimulate dentin production (pulp capping)	
Tooth pulp	GDF 11	Same purpose	[67,171,172]
	Ad-BMP-7		[173]
TMJ	Ad-LacZ reporter	TMJ articular surface targeting	[174]
Periodontal tissues	Ad-PDGF-B	Periodontal regeneration	[175]
	Ad-BMP-7	Periodontal regeneration	[50]
Peri-implant bone	Ad-BMP-7	Bone regeneration	[153]

AAV: Adeno-associated virus; BMP: Bone morphogenetic protein; Ad: Adenovirus; GDF: Growth/differentiation factor; *LacZ*: β -Galactosidase/*LacZ*; Platelet-derived growth factor; Retro: Retrovirus; TMJ: Temporomandibular joint; VEGF: Vascular endothelial growth factor.